reAlpha Tech Corp., ProMIS Neurosciences, and Incannex Healthcare Ltd. are the 3 Penny Stocks to watch on July 22, 2025, based on TipRanks’ Penny Stock Screener tool. Penny stocks are defined as stocks that trade at or below $5 per share and have a market capitalization below $300 million.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The Penny Stock Screener helps investors scan stocks based on numerous parameters, including Sector, Price Target Upside, Smart Score, Analyst Consensus, Dollar Volume, and Price Change.
We leveraged the tool to pick the top three penny stocks with the highest Dollar Volume as of the close on July 21, 2025. Simply put, Dollar Volume is the number of shares traded on a particular day multiplied by the day’s share price.
reAlpha Tech Corp. (AIRE) – reAlpha Tech is a real estate technology platform that offers an end-to-end commission-free home buying experience. On July 21, AIRE had a Dollar Volume of $670.98 million, while its stock price skyrocketed by 347.2%.
Yesterday, reAlpha announced that it has entered into definitive agreements for the purchase and sale of 14.29 million shares of its common stock at a purchase price of $0.35 per share in a registered direct offering priced at-the-market under Nasdaq rules. The company expects to raise roughly $5 million in gross proceeds from the offering, which will be used for working capital and general corporate purposes.
ProMIS Neurosciences (PMN) – ProMIS Neuroscience is a clinical-stage biotechnology company focused on developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD). Yesterday, PMN stock had a Dollar Volume of $325.25 million, accompanied by a stock price surge of 154%.
The company was granted Fast Track designation for PMN310 by the U.S. Food and Drug Administration (FDA). The drug is being tested as a potential treatment for Alzheimer’s disease. PMN310 is currently undergoing a Phase 1b trial, with interim results expected in Q2 2026 and final results in Q4 2026.
Incannex Healthcare Ltd. (IXHL) – Australia-based Incannex Healthcare is a clinical-stage biopharmaceutical company developing treatments for chronic conditions such as obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder. On Monday, IXHL had a Dollar Volume of $287.61 million, while its shares rose by more than 34%.
There was no specific news about Incannex yesterday to justify its stock price rally.
To find more penny stocks like these, you can take a look at TipRanks’ Penny Stock Screener tool. It shows a list of all penny stocks, their price movement, and other vital data.